



IFW

PATENT  
Customer No. 22,852  
New Attorney Docket No. 09963.0008

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: )  
Robert Hugh Bradbury et al. ) Examiner: Not Yet Assigned  
Application No.: 10/571,991 )  
Filed: March 15, 2006 )  
For: QUINAZOLINE DERIVATIVES )

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

**Supplemental Information Disclosure Statement Under 37 C.F.R. § 1.97(b)**

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicants bring to the attention of the Examiner the documents on the attached listing. This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits for the above-referenced application.

A copy of each of the listed non-patent literature documents is attached.

Applicants respectfully request that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached form.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the

documents as prior art against any claim in the application and applicants determine that the cited documents do not constitute "prior art" under United States law, Applicants reserve the right to present to the Office the relevant facts and law regarding the appropriate status of such documents.


Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.


If there is any fee due in connection with the filing of this Statement, please charge the fee to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,  
GARRETT & DUNNER, L.L.P.

Dated: January 9, 2007

By:   
Michele C. Bosch  
Reg. No. 40,524

IDS Form PTO/SB/08: Substitute for form 1449A/PTO  <div style="text-align: center;">   <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>          (Use as many sheets as necessary)       </div>				<b>Complete if Known</b>	
		Application Number		10/571,991	
		Filing Date		March 15, 2006	
		First Named Inventor		Robert BRADBURY	
		Art Unit		Not Yet Assigned	
		Examiner Name		Not Yet Assigned	
Sheet		1	of	1	Attorney Docket Number
		09963.0008-00000			

U.S. PATENTS AND PUBLISHED U.S. PATENT APPLICATIONS					
Examiner Initials	Cite No.	Document Number	Issue or Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code (if known)			

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No.	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation
		Country Code Number Kind Code (if known)				

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation
		Ballard, Peter et al, "5-Substituted 4-anilinoquinazolines as potent, selective and orally active inhibitors of erbB2 receptor tyrosine kinase," <i>Bioorganic &amp; Medicinal Chemistry Letters</i> 15(19):4226-4229 (2005).	
		Hennequin, Laurent et al, "Novel 4-anilinoquinazolines with C-6 carbon-linked side chains: Synthesis and structure-activity relationship of a series of potent, orally active, EGF receptor tyrosine kinase inhibitors," <i>Bioorganic &amp; Medicinal Chemistry Letters</i> 16(10):2672-2676 (2006).	
		Ballard, Peter et al, "Inhibitors of epidermal growth factor receptor tyrosine kinase: Novel C-5 substituted anilinoquinazolines designed to target the ribose pocket," <i>Bioorganic &amp; Medicinal Chemistry Letters</i> 16(6):1633-1637 (2006).	
		Ballard, Peter et al, "Inhibitors of epidermal growth factor receptor tyrosine kinase: Optimization of potency and in vivo pharmacokinetics," <i>Bioorganic &amp; Medicinal Chemistry Letters</i> 16(18):4908-4912 (2006).	
		Harris, Craig et al, "Selective alkylation of a 6,7-dihydroxyquinazoline," <i>Tetrahedron Letters</i> 46(45):7715-7719 (2005).	
		Harris, Craig et al, "Facile synthesis of 7-amino anilinoquinazolines via direct amination of the quinazoline core," <i>Tetrahedron Letters</i> 46(43):7381-7384 (2005).	

Examiner Signature	Date Considered	
-----------------------	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.